Does skyrizi cause upper respiratory infections as a side effect?

Does Skyrizi cause upper respiratory infections?

Skyrizi (risankizumab-rzaa) belongs to the interleukin-23 inhibitor class and often produces upper respiratory infections as a common side effect. In clinical trials, 13% of patients on Skyrizi experienced nasopharyngitis and 8% experienced upper respiratory tract infections, rates modestly higher than placebo.

Why do upper respiratory infections occur with Skyrizi?

The mechanism involves blocking IL-23, which weakens parts of the immune system responsible for fighting bacteria and fungi. This can increase susceptibility to infections in the nose, throat, and upper airways. Patients with active infections should not start Skyrizi until they clear them.

What other infections are patients asking about?

Patients also report increased rates of tinea infections (fungal skin infections), herpes simplex reactivation, and tuberculosis reactivation. Clinical data show tinea rates at 4% versus 2% in placebo. Patients must be screened for latent tuberculosis before starting treatment.

How does Skyrizi compare with other IL-23 inhibitors?

Tremfya and Ilumya show similar infection rates, including upper respiratory infections. All three drugs require tuberculosis screening and patient counseling about infection risk.